E-MAIL UPDATES

Click here to join

Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports

Analyst Reports
October 16th 2021

On the right pathway - Initiating coverage with a Buy Rating of A$1.19 TP (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

October 13th 2021

Corporate Connect - A Truly Undervalued Company – Target Price of A$2.20 (ASX:IMM) (Analyst: Marc Sinatra)

September 20th 2021

Maxim Group - The Case for LAG-3 is Building

August 30th 2021

Maxim Group - Annual FY Update; AIPAC Final Data Approaching

August 3rd 2021

New Age Immune Regulator - Initiate with a Buy Rating of US$8.30 TP (NASDAQ:IMMP) (Analyst: Ahu Demir)

July 16th 2021

Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 TP

July 14th 2021

Bell Potter - Creating Value with Phase 3 around the corner – Increasing TP to AUD 1.00 (from AUD 0.85)

July 6th 2021

goetzpartners securities -LAG-3 therapies taking immunology to the next level - Increasing TP to AUD 1.35 (from AUD 1.24)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

July 6th 2021

Taylor Collison - Efti development program expanded - Increasing TP to AUD 1.19 (from AUD 0.85)

For a copy of this research report please contact your Taylor Collison advisor.

June 10th 2021

Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 Immunotherapy — increasing to US$9 (from US$6)

June 5th 2021

goetzpartners securities - Efti combos move towards centre stage at ASCO : Increasing TP to A$1.24 (from A$0.90)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 4th 2021

Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares Remain Undervalued

May 20th 2021

goetzpartners securities - BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

May 3rd 2021

Corporate Connect - Efti a highly sought after compound for mono & combo Cancer treatment

April 9th 2021

Bell Potter - Efti granted Fast Track - A vote of confidence (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

April 8th 2021

Alliance Global Partners - FDA's Fast Track for Efti Suggests Regulators Echo Large Pharma Enthusiasm Surrounding LAG-3 Immunotherapy

March 31st 2021

Bell Potter - Validation for LAG-3 arrives (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

March 25th 2021

goetzpartners securities - BMS Study Identifies LAG-3 - PD-1 as Potential 'Key Strategy'

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 25th 2021

Maxim Group - Bristol Brings LAG-3 to the Forefront in Checkpoints with First Positive P3 Trial; Bodes Well for Efti and LAG-3 Pipeline

March 16th 2021

goetzpartners securities - Targeting first-line head and neck with Merck & Co

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 16th 2021

Maxim Group - Success in 2L H&N Cancer Leads to Second Collaboration to Move into 1L – Reiterate Buy

March 5th 2021

Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 25th 2021

Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 5th 2021

Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

January 26th 2021

Alliance Global Partners - Raising PT to $6 from $5; MBC Program Thrown a Lifeline by OS Data as IMMP Shares Find Their Heading for the Year of the Sea Shanty

December 14th 2020

goetzpartners securities - Door re-opens to first eftilagimod alpha approval

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

December 10th 2020

Maxim - Efti Was Out in Breast Cancer...Or Was it? Update from Ongoing SABCS meeting, Raising PT to $8

November 19th 2020

Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete

November 11th 2020

Maxim - The Data for Efti in Lung and H&N Continues to Build – Raising PT to $4, from $2

November 11th 2020

goetzpartners securities - Striking support for efti - checkpoint inhibitor combos

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

November 3rd 2020

Maxim - TACTI-002 Data (efti + pembro) to be Presented at SITC Meeting; Late Breaker Poster

October 27th 2020

Bell Potter - Efti now tackling COVID-19 (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

September 18th 2020

Taylor Collison - Immutep (IMM) Further positive efti data at ESMO

September 17th 2020

Bell Potter - Underappreciated immunotherapy player with leadership in LAG-3 (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

August 26th 2020

Taylor Collison - BMS/Dragonfly deal drives valuation upgrade

June 3rd 2020

goetzpartners securities - ASCO data underscores efti-PD-1 / L1 synergy

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 3rd 2020

Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

June 2nd 2020

JonesTrading - Responses to Efti + Pembro are Deepening Over Time, as is the Combo’s Market Opportunity with ASCO Data Positing Promise in New Indications

May 14th 2020

goetzpartners securities - First in class opening the cancer immune throttle

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 29th 2020

Maxim - Data From TACTI-002 Continues to be Positive, Activity In the Space Bodes Well for Immutep

April 22nd 2020

Taylor Collison - Immutep (IMM) Leading not LAGging

March 27th 2020

Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

March 26th 2020

JonesTrading - AIPAC Setback Leaves a Mark on Efti’s Otherwise Impeccable Clinical Report Card, but Don’t Warrant a Failing Grade for Immutep

March 26th 2020

goetzpartners securities - Efti breast trial: Down certainly not out

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

February 24th 2020

JonesTrading - Efti + Pembro Value Proposition in NSCLC is Crystallizing as TACTI-002 Suggests Combo is Competitively Effective and Far More Tolerable

February 19th 2020

Maxim - Valuation is Rising as First of 2 Key Catalysts Delivers (TACTI-002 in Lung Cancer, H&N); Breast Cancer P2b is Next (CY1Q20)

February 19th 2020

goetzpartners securities - Efti-pembro combo: A new option in NSCLC?

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

February 18th 2020

Bell Potter - Global leader in LAG-3, the hottest emerging immune checkpoint (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

January 30th 2020

Maxim - Inflection Points Approaching- Lung Cancer Data (February), Breast Cancer Data (March)

January 10th 2020

Maxim - TACTI-002 Head & Neck Cancer Study is Expanding, Data Updates Over 2020 – Reiterate Buy

October 28th 2019

Maxim - Runway Through CY20, Upcoming Catalysts ShouldContinue to Drive a Higher Valuation

October 15th 2019

goetzpartners securities - TACTI-mel final data confirm efficacy signals

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 26th 2019

goetzpartners securities - Positive interim analysis for TACTI-002

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 23rd 2019

Maxim - GSK Initiates New Trial for IMP731-Derived Therapy, Triggers Milestone to Immutep

September 23rd 2019

goetzpartners securities - Unlockgoetzpartners securities - £4M from GSK extend cash runway to YE2020E

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

July 2nd 2019

Edison - AIPAC fully recruited, results due Q120

April 30th 2019

Maxim - Immutep Provides Corporate Update, Data Points Ahead in 2019

April 23rd 2019

goetzpartners securities - Unlocking the value of LAG-3 in autoimmunity

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 8th 2019

Edison - Encouraging results for efti and IMP761

March 27th 2019

LifeSci Capital - Immutep Ltd (IMMP) Positive Signals in Pre-Clinical Studies with IMP761

March 8th 2019

Maxim - Checkpoints on the Flipside of Immune Oncology... Autoimmune disease - Immutep’s LAG-3 IMP761 Highlighted at ECCO

March 6th 2019

Maxim - Advancing the Second Merck Collaboration, TACTI-002 Doses First Patient

March 6th 2019

LifeSci Capital - Immutep Ltd (IMMP) Presents Updated Data from Ongoing TACTI-Mel Study

February 28th 2019

Maxim - Half Year Update: Expecting Data Updates from the LAG3Pipeline in 2019

February 5th 2019

goetzpartners securities - 2019 a decisive year rich in news flow

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

February 1st 2019

Maxim - Provides Update- Catalysts Ahead in 2019 in Several Programs around LAG-3

November 27th 2018

Maxim - More TACTI-mel Data Presented at the Annual ICI Europe Summit

November 21st 2018

Edison - A big year ahead for efti

November 13th 2018

Maxim – Immutep Presents “efti” (LAG-3) Data at SITC Summary

November 2nd 2018

goetzpartners securities - Pipeline on track at operational update

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

October 30th 2018

Maxim – Pipeline Update: Catalysts Ahead in the LAG-3 Franchise

October 18th 2018

LifeSci Capital Initiates Coverage of Immutep (IMMP)

September 28th 2018

B Riley FBR - Leading the LAG-3 Immunotherapy Charge into Immuno-oncology and Autoimmune Disease – Initiating Coverage

September 27th 2018

goetzpartners securities - Key takeaways from investor meetings in London

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 27th 2018

Edison - Merck /Pfizer collaboration - A second big pharma collaboration for efti

September 24th 2018

Maxim - GSK, Novartis, Merck... Now Merck KGAA and Pfizer... Pharma Collaborations Expand for LAG-3 Pipeline

August 30th 2018

Edison Research - LAG-3 Progress In-House and Via Partner

August 8th 2018

Maxim – Pipeline Update: Eftilagimod Moves Forward, Partners are Busy - Novartis, GSK, EOC (China)

July 31st 2018

Maxim – First US-Based Study of IMP321 Gets Green Light from FDA, Initiating 2H18

July 30th 2018

Maxim – Reports June Quarter: Cash Runway Through Several Data Points in the LAG-3 Pipeline

July 27th 2018

Maxim – Update on the LAG-3 Landscape; Immutep's Partners are Busy

July 12th 2018

goetzpartners securities - Targeting the LAG-3 immune checkpoint

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

July 2nd 2018

Maxim - First IND Filed in US for IMP321 (eftilagimod), Phase 2 Study with Keytruda 2H18

June 4th 2018

Partner Novartis Presents Early Efficacy Signal Data for LAG525 + PD1

May 25th 2018

IMP321 + Keytruda Data Continues to be Positive in Melanoma, ASCO Next - Raising Price Target to $7

March 29th 2018

Merck collaboration opens new opportunities

March 23rd 2018

IMP321 (LAG-3Ig) + Keytruda in Melanoma - Expansion Cohort Initiates Dosing

March 15th 2018

Maxim - Raises Capital ($5.4M), Extends Runway as IMP321 Expands to a New Combination Study with Keytruda

February 17th 2018

Maxim - Lowering Price Target to $5

February 2nd 2018

Maxim - LAG-3; The Next Emerging Checkpoint in Immune Oncology

December 12th 2017

EDISON - Encouraging LAG-3 combo data at SITC

November 28th 2017

Maxim - IMP321 + Keytruda: Positive Data in Melanoma to be Presented at SITC

November 15th 2017

Maxim - IMP321 (LAG-3Ig) Heating up the T cell Response for Keytruda in Melanoma - New Data To Be Presented at-SITC

October 10th 2017

Edison - Support for anti-LAG-3 and APC-activator combos

September 6th 2017

Edison - Support for Anti-Lag-3 and APC-Activators Combos

August 1st 2017

Maxim Research - Understanding LAG-3 Function in Controlling T Cells- Grant Funding Awarded to Prima

July 1st 2017

Maxim PBMD Report - Coming to the Next Checkpoint: LAG-3 and Prima has the Right Partner in Novartis

June 1st 2017

Edison - Preliminary LAG-3 combo data in breast cancer

March 1st 2017

Edison - Initial LAG-3 combo data presented

February 1st 2017

H.C. Wainwright - Looking Ahead to a Catalyst-Rich 2017; Reiterate Buy

February 1st 2017

Edison - Prima BioMed - AIPAC Phase IIb starts randomized component

January 1st 2017

FRB & Co. - Green Shoots from Broad Clinical Progress Are Emerging

January 1st 2017

Research Note – Ongoing strong data support LAG-3 pipeline

December 30th 2016

Maxim Group - LAG-3 + Keytruda: Safe So Far - Moving to Higher Dose; Adjusting Model for New ADR Ratio and Reducing Price Target

November 23rd 2016

Maxim Group - Expanding the Footprint in China - WuXi Biologics Comes On Board for Manufacturing of IMP321